|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TTLL1 |
Gene summary for TTLL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TTLL1 | Gene ID | 25809 |
| Gene name | tubulin tyrosine ligase like 1 | |
| Gene Alias | C22orf7 | |
| Cytomap | 22q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R4U6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25809 | TTLL1 | LZE2T | Human | Esophagus | ESCC | 4.73e-03 | 2.95e-01 | 0.082 |
| 25809 | TTLL1 | LZE24T | Human | Esophagus | ESCC | 1.68e-09 | 2.46e-01 | 0.0596 |
| 25809 | TTLL1 | P1T-E | Human | Esophagus | ESCC | 4.62e-03 | 1.71e-01 | 0.0875 |
| 25809 | TTLL1 | P2T-E | Human | Esophagus | ESCC | 9.20e-06 | 1.28e-01 | 0.1177 |
| 25809 | TTLL1 | P4T-E | Human | Esophagus | ESCC | 1.75e-05 | 1.36e-01 | 0.1323 |
| 25809 | TTLL1 | P8T-E | Human | Esophagus | ESCC | 3.50e-02 | 8.82e-02 | 0.0889 |
| 25809 | TTLL1 | P10T-E | Human | Esophagus | ESCC | 2.39e-24 | 3.88e-01 | 0.116 |
| 25809 | TTLL1 | P11T-E | Human | Esophagus | ESCC | 4.74e-03 | 1.49e-01 | 0.1426 |
| 25809 | TTLL1 | P12T-E | Human | Esophagus | ESCC | 3.89e-12 | 1.83e-01 | 0.1122 |
| 25809 | TTLL1 | P15T-E | Human | Esophagus | ESCC | 1.32e-06 | 1.67e-01 | 0.1149 |
| 25809 | TTLL1 | P16T-E | Human | Esophagus | ESCC | 1.85e-18 | 3.29e-01 | 0.1153 |
| 25809 | TTLL1 | P21T-E | Human | Esophagus | ESCC | 3.63e-05 | 9.01e-02 | 0.1617 |
| 25809 | TTLL1 | P22T-E | Human | Esophagus | ESCC | 9.44e-07 | 1.40e-01 | 0.1236 |
| 25809 | TTLL1 | P23T-E | Human | Esophagus | ESCC | 9.87e-03 | 1.13e-01 | 0.108 |
| 25809 | TTLL1 | P24T-E | Human | Esophagus | ESCC | 1.66e-02 | 8.92e-02 | 0.1287 |
| 25809 | TTLL1 | P26T-E | Human | Esophagus | ESCC | 9.02e-11 | 1.99e-01 | 0.1276 |
| 25809 | TTLL1 | P27T-E | Human | Esophagus | ESCC | 3.89e-12 | 1.97e-01 | 0.1055 |
| 25809 | TTLL1 | P30T-E | Human | Esophagus | ESCC | 1.89e-05 | 2.02e-01 | 0.137 |
| 25809 | TTLL1 | P31T-E | Human | Esophagus | ESCC | 9.20e-06 | 1.35e-01 | 0.1251 |
| 25809 | TTLL1 | P32T-E | Human | Esophagus | ESCC | 8.84e-05 | 9.79e-02 | 0.1666 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00603384 | Oral cavity | OSCC | regulation of type I interferon-mediated signaling pathway | 28/7305 | 36/18723 | 2.45e-06 | 3.08e-05 | 28 |
| GO:00607594 | Oral cavity | OSCC | regulation of response to cytokine stimulus | 92/7305 | 162/18723 | 3.25e-06 | 3.90e-05 | 92 |
| GO:00028324 | Oral cavity | OSCC | negative regulation of response to biotic stimulus | 65/7305 | 108/18723 | 6.62e-06 | 7.29e-05 | 65 |
| GO:00450884 | Oral cavity | OSCC | regulation of innate immune response | 116/7305 | 218/18723 | 1.36e-05 | 1.37e-04 | 116 |
| GO:00192214 | Oral cavity | OSCC | cytokine-mediated signaling pathway | 222/7305 | 472/18723 | 2.02e-04 | 1.35e-03 | 222 |
| GO:000268310 | Oral cavity | OSCC | negative regulation of immune system process | 204/7305 | 434/18723 | 3.72e-04 | 2.27e-03 | 204 |
| GO:00458244 | Oral cavity | OSCC | negative regulation of innate immune response | 41/7305 | 71/18723 | 1.05e-03 | 5.40e-03 | 41 |
| GO:00507774 | Oral cavity | OSCC | negative regulation of immune response | 97/7305 | 194/18723 | 1.16e-03 | 5.91e-03 | 97 |
| GO:0060339 | Oral cavity | OSCC | negative regulation of type I interferon-mediated signaling pathway | 15/7305 | 20/18723 | 1.19e-03 | 5.99e-03 | 15 |
| GO:003434012 | Oral cavity | LP | response to type I interferon | 34/4623 | 58/18723 | 3.84e-08 | 1.37e-06 | 34 |
| GO:000734614 | Oral cavity | LP | regulation of mitotic cell cycle | 163/4623 | 457/18723 | 7.64e-08 | 2.56e-06 | 163 |
| GO:007135712 | Oral cavity | LP | cellular response to type I interferon | 31/4623 | 52/18723 | 8.89e-08 | 2.93e-06 | 31 |
| GO:006033712 | Oral cavity | LP | type I interferon signaling pathway | 30/4623 | 50/18723 | 1.17e-07 | 3.78e-06 | 30 |
| GO:00603381 | Oral cavity | LP | regulation of type I interferon-mediated signaling pathway | 21/4623 | 36/18723 | 1.74e-05 | 2.99e-04 | 21 |
| GO:000283211 | Oral cavity | LP | negative regulation of response to biotic stimulus | 46/4623 | 108/18723 | 3.31e-05 | 5.02e-04 | 46 |
| GO:000195911 | Oral cavity | LP | regulation of cytokine-mediated signaling pathway | 58/4623 | 150/18723 | 1.00e-04 | 1.24e-03 | 58 |
| GO:004508811 | Oral cavity | LP | regulation of innate immune response | 78/4623 | 218/18723 | 1.57e-04 | 1.78e-03 | 78 |
| GO:00603391 | Oral cavity | LP | negative regulation of type I interferon-mediated signaling pathway | 13/4623 | 20/18723 | 1.59e-04 | 1.79e-03 | 13 |
| GO:006075911 | Oral cavity | LP | regulation of response to cytokine stimulus | 61/4623 | 162/18723 | 1.61e-04 | 1.81e-03 | 61 |
| GO:000283112 | Oral cavity | LP | regulation of response to biotic stimulus | 109/4623 | 327/18723 | 2.45e-04 | 2.60e-03 | 109 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TTLL1 | SNV | Missense_Mutation | c.1204N>G | p.Gln402Glu | p.Q402E | O95922 | protein_coding | tolerated_low_confidence(0.59) | benign(0.01) | TCGA-A2-A0YL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| TTLL1 | SNV | Missense_Mutation | novel | c.175G>T | p.Asp59Tyr | p.D59Y | O95922 | protein_coding | tolerated(0.22) | benign(0.087) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TTLL1 | SNV | Missense_Mutation | novel | c.200N>G | p.Asn67Ser | p.N67S | O95922 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| TTLL1 | insertion | Frame_Shift_Ins | novel | c.1266_1267insGCTC | p.Lys423AlafsTer30 | p.K423Afs*30 | O95922 | protein_coding | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| TTLL1 | SNV | Missense_Mutation | novel | c.447N>G | p.Phe149Leu | p.F149L | O95922 | protein_coding | deleterious(0) | possibly_damaging(0.861) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| TTLL1 | SNV | Missense_Mutation | novel | c.331N>G | p.Pro111Ala | p.P111A | O95922 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| TTLL1 | SNV | Missense_Mutation | rs774349127 | c.730G>A | p.Ala244Thr | p.A244T | O95922 | protein_coding | deleterious(0) | probably_damaging(0.941) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TTLL1 | SNV | Missense_Mutation | novel | c.1135G>A | p.Glu379Lys | p.E379K | O95922 | protein_coding | tolerated(0.07) | benign(0.063) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TTLL1 | SNV | Missense_Mutation | rs368878876 | c.535G>A | p.Val179Met | p.V179M | O95922 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TTLL1 | SNV | Missense_Mutation | rs867699587 | c.949N>A | p.Asp317Asn | p.D317N | O95922 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |